A. V. Pushkarev
A. V. Pushkarev has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Konstantin V. Menshikov
Republican Clinical Oncology Dispensary; Bashkir State Medical University
3 shared publications - V. A. Pushkarev
Republican Clinical Oncologic Dispensary
3 shared publications - Александр Валерьевич Султанбаев
Bashkir State Medical University; Republican Clinical Oncology Dispensary
3 shared publications - Adel A. Izmailov
Republican Clinical Oncology Dispensary; Bashkir State Medical University
2 shared publications - Ainur F. Nasretdinov
Republican Clinical Oncology Dispensary
2 shared publications - Marat Mirsayafovich Galeev
Republican Clinical Oncology Dispensary
2 shared publications
Latest Publications
- Open Access
- 8 February 2025
- Published by Research Institute of Microsurgery in Issues of Reconstructive and Plastic Surgery
- Vol. 27 (4) , 53-67
Study of the main histopathological characteristics of a cadaveric fascia lata allomaterial in an in vivo experiment
Objective. The fascia lata allomaterial (FLA) has been successfully used in ophthalmology, dentistry, thoracic surgery, neurosurgery, and other fields. However, data on its application in breast reconstruction are extremely limited.Purpose of a study: to conduct a randomized controlled experimental investigation of the histological and biomechanical characteristics of cadaveric fascia lata allomaterial (alloplant®) compared to other allomaterials used in breast reconstruction.Material and Methods. The study involved 30 white outbred rats, randomly divided into 3 groups (10 animals each): xenograft, synthetic mesh, and FLA. On days 1, 3, 7, 10, and 14 post-surgery, the implants were removed en bloc for histological analysis, focusing on neovascularization, fibrosis, inflammatory response, and collagen fiber organization. Additionally, the thickness of the inflammatory infiltrate and the lysis surface area were assessed.Results. In the FLA group, inflammatory cells infiltrated the matrix surface more actively at both the beginning and end of the experiment compared to the other groups (p < 0.05). The most active resorption occurred in the synthetic mesh group, while the lowest lysis rate, particularly in the second week, was observed in the xenograft group. The FLA showed superior fibrosis (p < 0.05), inflammatory infiltrate (p < 0.05), and collagen organization (p < 0.05) compared to the synthetic mesh.Conclusion. The cadaveric fascia lata allograft in a rat model demonstrated slower biodegradation compared to a synthetic mesh, with no statistically significant difference from the xenograft group.
- 8 February 2025
- Published by Research Institute of Microsurgery in Issues of Reconstructive and Plastic Surgery
- Vol. 27 (4) , 53-67
Open AccessStudy of the main histopathological characteristics of a cadaveric fascia lata allomaterial in an in vivo experiment
Objective. The fascia lata allomaterial (FLA) has been successfully used in ophthalmology, dentistry, thoracic surgery, neurosurgery, and other fields. However, data on its application in breast reconstruction are extremely limited.Purpose of a study: to conduct a randomized controlled experimental investigation of the histological and biomechanical characteristics of cadaveric fascia lata allomaterial (alloplant®) compared to other allomaterials used in breast reconstruction.Material and Methods. The study involved 30 white outbred rats, randomly divided into 3 groups (10 animals each): xenograft, synthetic mesh, and FLA. On days 1, 3, 7, 10, and 14 post-surgery, the implants were removed en bloc for histological analysis, focusing on neovascularization, fibrosis, inflammatory response, and collagen fiber organization. Additionally, the thickness of the inflammatory infiltrate and the lysis surface area were assessed.Results. In the FLA group, inflammatory cells infiltrated the matrix surface more actively at both the beginning and end of the experiment compared to the other groups (p < 0.05). The most active resorption occurred in the synthetic mesh group, while the lowest lysis rate, particularly in the second week, was observed in the xenograft group. The FLA showed superior fibrosis (p < 0.05), inflammatory infiltrate (p < 0.05), and collagen organization (p < 0.05) compared to the synthetic mesh.Conclusion. The cadaveric fascia lata allograft in a rat model demonstrated slower biodegradation compared to a synthetic mesh, with no statistically significant difference from the xenograft group.
- 20 September 2023
- Published by Media Sphere Publishing Group in Plastic Surgery and Aesthetic Medicine
- No. 3
Acellular dermal matrices in breast reconstruction
Acellular dermal matrices (ADM) have been successfully used in reconstructive surgery for more than two decades. These matrices are safe and effective products with minimal complication rates. In breast reconstructions, acellular dermal matrices have been used since 2001. They are applied as a 3D mesh for ingrowth of connective tissue cells and other elements necessary for a stable frame. These matrices reduced the incidence of repeated procedures for tissue expansion, capsular contractures, postoperative pain syndrome, multi-stage surgeries, etc. Nevertheless, these products have certain disadvantages associated with higher incidence of such complications as skin flap necrosis, infection and seroma. Despite numerous studies devoted to ADM in reconstructions, there is still small number of high-quality prospective studies devoted to benefits and side effects of these products in breast reconstruction.
- 20 September 2023
- Published by Media Sphere Publishing Group in Plastic Surgery and Aesthetic Medicine
- No. 3
Acellular dermal matrices in breast reconstruction
Acellular dermal matrices (ADM) have been successfully used in reconstructive surgery for more than two decades. These matrices are safe and effective products with minimal complication rates. In breast reconstructions, acellular dermal matrices have been used since 2001. They are applied as a 3D mesh for ingrowth of connective tissue cells and other elements necessary for a stable frame. These matrices reduced the incidence of repeated procedures for tissue expansion, capsular contractures, postoperative pain syndrome, multi-stage surgeries, etc. Nevertheless, these products have certain disadvantages associated with higher incidence of such complications as skin flap necrosis, infection and seroma. Despite numerous studies devoted to ADM in reconstructions, there is still small number of high-quality prospective studies devoted to benefits and side effects of these products in breast reconstruction.
- Open Access
- 5 November 2022
- Published by Ural State Medical University in Ural Medical Journal
- Vol. 21 (5) , 128-137
Benign breast tumors and risk factors for their development
Introduction. Benign mammary gland tumors constitute a group of heterogeneous diseases with a complex clinical and morphological structure that complicates timely diagnosis and terminological designation of pathological processes. They are of great interest because of their possible background for oncologic pathology. The most widespread disease is mastopathy, its occurrence rate in the population reaches 40%. The incidence of mastopathies increases by the age of 45 years, and then tends to decrease in the pre- and postmenopausal periods. The purpose of the review was to evaluate and analyze the literature data on the presented problem in recent years. Materials and methods. Publications of domestic and foreign authors on benign breast neoplasms and risk factors of this pathology over the past 20 years have been included in the article. Literature search was performed in the systems Scopus, Web of Science, PubMed, Elibrary. Results and discussion. Etiopathogenetic factors in patients with benign mammary gland tumors play a paramount role, substantiating the necessity of prognostication and prevention of the disease. Risk factors for these diseases include hereditary, hormonal, neuropsychological, reproductive data, age, lactation, inflammation, trauma, smoking, and others. Conclusion. The current dynamic of increasing the incidence of benign mammary tumors has been noted, but no specific risk factors for this group of diseases have been identified, as they are multifactorial, associated with genetic causes, somatic health data, and environmental influences. Not all women are equally at risk of developing breast diseases, the reasons characterizing the individual propensity for this pathology have been identified. The risk factors do not cause the development of the disease, but considerably increase its probability. The study of predisposing risk factors for the development of tumor processes in the mammary glands in order to diagnose them early gives an opportunity to improve the results and prognosis of treatment.
- 5 November 2022
- Published by Ural State Medical University in Ural Medical Journal
- Vol. 21 (5) , 128-137
Open AccessBenign breast tumors and risk factors for their development
Introduction. Benign mammary gland tumors constitute a group of heterogeneous diseases with a complex clinical and morphological structure that complicates timely diagnosis and terminological designation of pathological processes. They are of great interest because of their possible background for oncologic pathology. The most widespread disease is mastopathy, its occurrence rate in the population reaches 40%. The incidence of mastopathies increases by the age of 45 years, and then tends to decrease in the pre- and postmenopausal periods. The purpose of the review was to evaluate and analyze the literature data on the presented problem in recent years. Materials and methods. Publications of domestic and foreign authors on benign breast neoplasms and risk factors of this pathology over the past 20 years have been included in the article. Literature search was performed in the systems Scopus, Web of Science, PubMed, Elibrary. Results and discussion. Etiopathogenetic factors in patients with benign mammary gland tumors play a paramount role, substantiating the necessity of prognostication and prevention of the disease. Risk factors for these diseases include hereditary, hormonal, neuropsychological, reproductive data, age, lactation, inflammation, trauma, smoking, and others. Conclusion. The current dynamic of increasing the incidence of benign mammary tumors has been noted, but no specific risk factors for this group of diseases have been identified, as they are multifactorial, associated with genetic causes, somatic health data, and environmental influences. Not all women are equally at risk of developing breast diseases, the reasons characterizing the individual propensity for this pathology have been identified. The risk factors do not cause the development of the disease, but considerably increase its probability. The study of predisposing risk factors for the development of tumor processes in the mammary glands in order to diagnose them early gives an opportunity to improve the results and prognosis of treatment.
- Open Access
- 16 June 2021
- Published by Publishing House ABV Press in Tumors of female reproductive system
- Vol. 17 (1) , 35-44
Multilineal treatment strategy of HER2-positive metastatic breast cancer (clinical case)
Descripton of metastatic HER2-positive breast cancer clinical case is introduced, multilineal strategy basing on clinical situation and disease features is justified, justification of the choice of anti-HER2 treatment in every line is made, in compliance with russian and foreigh oncology associations guidelines, along with comparance of rutine treatment results and randomised trials data.
- 16 June 2021
- Published by Publishing House ABV Press in Tumors of female reproductive system
- Vol. 17 (1) , 35-44
Open AccessMultilineal treatment strategy of HER2-positive metastatic breast cancer (clinical case)
Descripton of metastatic HER2-positive breast cancer clinical case is introduced, multilineal strategy basing on clinical situation and disease features is justified, justification of the choice of anti-HER2 treatment in every line is made, in compliance with russian and foreigh oncology associations guidelines, along with comparance of rutine treatment results and randomised trials data.
- Open Access
- 21 December 2020
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 20,p. 40-46
Inhibitors of cyclin-dependent kinases 4/6 for breast cancer patients with different somatic mutations of the PIK3CA gene
Introduction. Breast cancer is the leader in cancer incidence in theRussian Federation. The tumor is considered extremely heterogeneous and the luminal subtypes of breast tumors occupy a special place, since they are considered relatively favorable in therapy and control of the disease.Drug therapy for hormone-positive cancer has undergone significant evolution and new anticancer agents have appeared in the arsenal of the oncologist and have shown promising results compared to classical therapy. The search for predictive markers of the effectiveness of new therapy has become of great importance. This marker turned out to be a mutation in the PIK3CA gene – one of the most frequent genetic disorders in breast cancer cells. According to the literature, the presence of this mutation negatively effects on endocrine therapy for breast tumors.The aim of this study was to analyze the frequency of mutations in the PIK3CA gene among patients with hormone-positive tumors, and the effectiveness of therapy with CDK4/6 inhibitors in this group of patients.Materials and methods. The material for the study of the mutation in the PIK3CA gene was tumor biopsies of 31 patients and clinical data on the response to therapy with CDK4/6 inhibitors and classical hormone therapy.Results and discussion. The results of the work showed a high incidence of the PIK3CA mutation among hormone-positive tumors (45%). The mutation resulted in a decrease in both the median time to progression after radical surgery (from 48.4 ± 7.8 months to 30.1 ± 6.0 months) in patients receiving adjuvant hormone therapy and progression-free survival in patients receiving therapy with CDK4 /6 inhibitors (4.2 months versus 9 months). This confirmed the theory that the PIK3CA mutation negatively affects the outcome of hormone therapy.Conclusions. PIK3CA is an important predictive marker in endocrine therapy for hormone-positive tumors. Its presence not only determines the relatively worse results of treatment, but can also serve as an indication for the appointment of a special series of drugs – inhibitors of this mutation.
- 21 December 2020
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 20,p. 40-46
Open AccessInhibitors of cyclin-dependent kinases 4/6 for breast cancer patients with different somatic mutations of the PIK3CA gene
Introduction. Breast cancer is the leader in cancer incidence in theRussian Federation. The tumor is considered extremely heterogeneous and the luminal subtypes of breast tumors occupy a special place, since they are considered relatively favorable in therapy and control of the disease.Drug therapy for hormone-positive cancer has undergone significant evolution and new anticancer agents have appeared in the arsenal of the oncologist and have shown promising results compared to classical therapy. The search for predictive markers of the effectiveness of new therapy has become of great importance. This marker turned out to be a mutation in the PIK3CA gene – one of the most frequent genetic disorders in breast cancer cells. According to the literature, the presence of this mutation negatively effects on endocrine therapy for breast tumors.The aim of this study was to analyze the frequency of mutations in the PIK3CA gene among patients with hormone-positive tumors, and the effectiveness of therapy with CDK4/6 inhibitors in this group of patients.Materials and methods. The material for the study of the mutation in the PIK3CA gene was tumor biopsies of 31 patients and clinical data on the response to therapy with CDK4/6 inhibitors and classical hormone therapy.Results and discussion. The results of the work showed a high incidence of the PIK3CA mutation among hormone-positive tumors (45%). The mutation resulted in a decrease in both the median time to progression after radical surgery (from 48.4 ± 7.8 months to 30.1 ± 6.0 months) in patients receiving adjuvant hormone therapy and progression-free survival in patients receiving therapy with CDK4 /6 inhibitors (4.2 months versus 9 months). This confirmed the theory that the PIK3CA mutation negatively affects the outcome of hormone therapy.Conclusions. PIK3CA is an important predictive marker in endocrine therapy for hormone-positive tumors. Its presence not only determines the relatively worse results of treatment, but can also serve as an indication for the appointment of a special series of drugs – inhibitors of this mutation.
- Open Access
- 27 October 2020
- Published by ECO-Vector LLC in Kazan medical journal
- Vol. 101 (5) , 691-697
Spectrum and frequency of BRCA1, BRCA2, CHEK2, PALB2, RAD50 mutations in breast cancer patients in the Republic of Bashkortostan
Aim. To assess the spectrum and frequency of mutations in patients with hereditary breast cancer from the Republic of Bashkortostan. Methods. The material for the study was sections of fresh frozen, formalin-fixed and paraffin-embedded tumor tissue from 100 unrelated patients with a histologically confirmed diagnosis of breast cancer. The study was carried out using two methods: real-time polymerase chain reaction and next-generation sequencing-NGS. Results. By using real-time polymerase chain reaction (PCR), the 5382insC mutation in the BRCA1 gene was detected in 12 cases. By using a next-generation sequencing method (NGS), highly penetrant mutations in BRCA1, BRCA2, CHEK2, PALB2 and RAD50 were revealed in 16 patients. In total, these methods detected mutations in 28 patients. Out of a total of probands in the BRCA1 gene, mutations were detected in 13 patients, that included 12 patients with the 5382insC mutation, and 1 patient with c.3143delG. In the BRCA2 gene, mutations were revealed in 3 patients, of which c.6621_6622del in 2 patients and c.-39-1_-39delGA in 1 patient. Mutations in CHEK2 were detected in 5 patients: c.470TC in 3 patients, c.444+1GA in 2 patients. The 1592delT mutation in PALB2 was found in 4 patients. The c.2157delA mutation in RAD50 was detected in 3 patients. Conclusion. Pathogenic mutations in BRCA1/2, CHEK2, PALB2 and RAD50 were found in 28 patients with a hereditary feature of the disease; the identification of highly penetrant mutations in probands allowed us to determine their relatives, probable carriers of mutations, which were referred for genetic counselling.
- 27 October 2020
- Published by ECO-Vector LLC in Kazan medical journal
- Vol. 101 (5) , 691-697
Open AccessSpectrum and frequency of BRCA1, BRCA2, CHEK2, PALB2, RAD50 mutations in breast cancer patients in the Republic of Bashkortostan
Aim. To assess the spectrum and frequency of mutations in patients with hereditary breast cancer from the Republic of Bashkortostan. Methods. The material for the study was sections of fresh frozen, formalin-fixed and paraffin-embedded tumor tissue from 100 unrelated patients with a histologically confirmed diagnosis of breast cancer. The study was carried out using two methods: real-time polymerase chain reaction and next-generation sequencing-NGS. Results. By using real-time polymerase chain reaction (PCR), the 5382insC mutation in the BRCA1 gene was detected in 12 cases. By using a next-generation sequencing method (NGS), highly penetrant mutations in BRCA1, BRCA2, CHEK2, PALB2 and RAD50 were revealed in 16 patients. In total, these methods detected mutations in 28 patients. Out of a total of probands in the BRCA1 gene, mutations were detected in 13 patients, that included 12 patients with the 5382insC mutation, and 1 patient with c.3143delG. In the BRCA2 gene, mutations were revealed in 3 patients, of which c.6621_6622del in 2 patients and c.-39-1_-39delGA in 1 patient. Mutations in CHEK2 were detected in 5 patients: c.470TC in 3 patients, c.444+1GA in 2 patients. The 1592delT mutation in PALB2 was found in 4 patients. The c.2157delA mutation in RAD50 was detected in 3 patients. Conclusion. Pathogenic mutations in BRCA1/2, CHEK2, PALB2 and RAD50 were found in 28 patients with a hereditary feature of the disease; the identification of highly penetrant mutations in probands allowed us to determine their relatives, probable carriers of mutations, which were referred for genetic counselling.
- Open Access
- 26 July 2020
- Published by Bashkir State Medical University in Creative surgery and oncology
- Vol. 10 (2) , 143-148
Radiogenic Vaginal Angiosarcoma: a Clinical Case
Background. Vaginal sarcomas are rare malignant mesenchymal neoplasms. Incidence rate of vulvar and vaginal sarcomas ranges from 1 to 3%. Vaginal sarcomas are usually represented by leiomyosarcomas in reproductive-age women. More seldom are soft tissue fibrosarcomas, angiosarcomas, malignant fi brous histiocytomas and alveolar soft tissue sarcomas. Tumours induced by prior radiation therapy deserve special concern. In oncogynaecology, radiation therapy is commonly applied in cervical and endometrial cancer therapy. According to some evidence, average development time of a secondary tumour after completion of radiation therapy is 10.8 years. The relative risk of vaginal cancer increases by a factor of 300 after radiation therapy.Materials and methods. The reported clinical case represents a rare vaginal tumour, angiosarcoma, developed 26 years after radiation therapy for gynaecological cancer.Results and discussion. A 78 years-old patient underwent combined tumourectomy of the posterior vaginal wall with resection of the anterior rectal wall and application of preventive transversostoma. No postoperative complications were observed.Conclusion. Surgical treatment is a method of choice with patients of such kind and allows local containment of the disease.
- 26 July 2020
- Published by Bashkir State Medical University in Creative surgery and oncology
- Vol. 10 (2) , 143-148
Open AccessRadiogenic Vaginal Angiosarcoma: a Clinical Case
Background. Vaginal sarcomas are rare malignant mesenchymal neoplasms. Incidence rate of vulvar and vaginal sarcomas ranges from 1 to 3%. Vaginal sarcomas are usually represented by leiomyosarcomas in reproductive-age women. More seldom are soft tissue fibrosarcomas, angiosarcomas, malignant fi brous histiocytomas and alveolar soft tissue sarcomas. Tumours induced by prior radiation therapy deserve special concern. In oncogynaecology, radiation therapy is commonly applied in cervical and endometrial cancer therapy. According to some evidence, average development time of a secondary tumour after completion of radiation therapy is 10.8 years. The relative risk of vaginal cancer increases by a factor of 300 after radiation therapy.Materials and methods. The reported clinical case represents a rare vaginal tumour, angiosarcoma, developed 26 years after radiation therapy for gynaecological cancer.Results and discussion. A 78 years-old patient underwent combined tumourectomy of the posterior vaginal wall with resection of the anterior rectal wall and application of preventive transversostoma. No postoperative complications were observed.Conclusion. Surgical treatment is a method of choice with patients of such kind and allows local containment of the disease.